AstraZeneca green light to resume corona vaccine testing | Financial

The trials were previously halted due to medical problems with two subjects.

The FDA has completed its investigation into two cases of a possible neurological side effect in people receiving the drug. The FDA reportedly found no evidence that the vaccine was responsible for the two cases, although it couldn’t rule out a link either. AstraZeneca declined to comment.

Several pharmaceutical companies are working on a possible vaccine to prevent infection with the corona virus. AstraZeneca and Oxford are currently the furthest in that development. They are in the so-called clinical test phase 3. This is the last step before regulators have to decide whether a product can be marketed. The Netherlands and other European countries have already reserved millions of doses with AstraZeneca.

–